Skip to main content
NewslettersWatchlist

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Newswire.ca - Thu May 9, 3:01PM CDT

Pelareorep advancing to registration-enabling studies

Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).